Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab

18Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background. Post-transplant lymphoproliferative disorder (PTLD) occasionally presents as Burkitt lymphoma/L3 leukaemia (BLL). Procedure. We reviewed records of cases of PTLD post-cardiac transplantation (1990-2007) occurring in our unit. Results. There were 15 episodes in 13 patients including four cases of EBV-driven Burkitt-type disease with t(8;14) translocations presenting with advanced stage disease. The first case was treated with a variety of low dose chemotherapy combinations. Despite problems during therapy he obtained complete remission, but died from complications of pre-existing cardiac allograft vasculopathy 7 months later. The subsequent three cases were treated with a UKCCSG low stage lymphoma protocol, NHL 9001 and Rituximab. They remain in complete remission. Conclusions. In the context of PTLD the prognostic significance of advanced stage EBV-driven BLL with the t(8;14) translocation may be different to that in immunocompetent children. © 2009 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Windebank, K., Walwyn, T., Kirk, R., Parry, G., Hasan, A., Bown, N., & Wilkins, B. (2009). Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab. Pediatric Blood and Cancer, 53(3), 392–396. https://doi.org/10.1002/pbc.22070

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free